Literature DB >> 16008691

Epstein--Barr virus-associated B-cell lymphoma in the setting of iatrogenic immune dysregulation presenting initially in the skin.

Shannon Verma1, Gwyn E Frambach, Kay H Seilstad, Gerard Nuovo, Pierluigi Porcu, Cynthia M Magro.   

Abstract

BACKGROUND: Epstein-Barr virus (EBV) has been implicated in B-cell lymphoma associated with iatrogenic immune dysregulation, primarily in the context of extracutaneous lymphoma.
METHODS: We describe six patients, five transplant recipients receiving cyclosporine and one patient with rheumatoid arthritis receiving methotrexate, who developed cutaneous presentations of EBV-associated B-cell lymphoma. Human herpesvirus 8 (HHV8) and EBV thymidine kinase (vTK) expression were also explored.
RESULTS: The cases comprised plasmablastic lymphoma (one case), plasmacytic marginal zone lymphoma (two cases), and diffuse large B-cell lymphoma (three cases). There was a monoclonal gammopathy in one and concurrent extracutaneous disease in two of the six patients. EBV-associated latent small nuclear RNA was detected in all cases with coexpression of HHV8 in one of the five cases and of vTK in three of the six cases. Three patients responded to a reduction in the immunosuppressive regimen and antiviral therapy. Recurrent disease developed in two, with one patient succumbing to multiorgan dissemination.
CONCLUSIONS: EBV-associated cutaneous B-cell lymphoma is characterized by a long interval between the initiation of immunosuppression and the development of lymphoma. Although previous reports have reported an indolent clinical course, an aggressive clinical course may occur. HHV8 and lytic phase EBV antigens are detected in some cases, possibly suggesting a pathogenetic role.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16008691     DOI: 10.1111/j.0303-6987.2005.00363.x

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  7 in total

1.  [Malignant lymphoma of the skin: update on diagnostics and therapy of primary cutaneous B-cell lymphoma].

Authors:  C Hallermann; C Niermann; M Fluck; A-R Fischedick; H-J Schulze
Journal:  Hautarzt       Date:  2011-12       Impact factor: 0.751

2.  Expanding the Spectrum of EBV-positive Marginal Zone Lymphomas: A Lesion Associated With Diverse Immunodeficiency Settings.

Authors:  Shunyou Gong; Genevieve M Crane; Chad M McCall; Wenbin Xiao; Karthik A Ganapathi; Nathan Cuka; Theresa Davies-Hill; Liqiang Xi; Mark Raffeld; Stefania Pittaluga; Amy S Duffield; Elaine S Jaffe
Journal:  Am J Surg Pathol       Date:  2018-10       Impact factor: 6.394

3.  [Rare viral infections during immunosuppressive therapy: a "normal" side effect?].

Authors:  T Glück
Journal:  Z Rheumatol       Date:  2011-07       Impact factor: 1.372

4.  Epstein-Barr virus-positive primary cutaneous follicle centre lymphoma; an age-related phenomenon?

Authors:  Michiel P van der Horst; Alice Hardwick; Maeve Rahilly; John R Goodlad
Journal:  Virchows Arch       Date:  2015-05-10       Impact factor: 4.064

5.  Epstein-Barr Virus-negative Marginal Zone Lymphoma as an Uncommon Form of Monomorphic Posttransplant Lymphoproliferative Disorder.

Authors:  Pallavi Galera; Richard Flavin; Natasha M Savage; Annapurna Saksena; Shunyou Gong; Huan-You Wang; Niall Swan; Liqiang Xi; Mark Raffeld; Stefania Pittaluga; Elaine S Jaffe
Journal:  Am J Surg Pathol       Date:  2020-10       Impact factor: 6.298

6.  Cutaneous plasmablastic lymphoma in an immunocompetent patient with long-term pyrimethamine use for essential thrombocythemia: a case report and literature review.

Authors:  Ing Soo Tiong; Magreet Strauss; Michael B Y Lau; Shingirai Chiruka
Journal:  Case Rep Hematol       Date:  2013-02-06

7.  Methotrexate-induced CD30(+) T-cell lymphoproliferative disorder of the oral cavity.

Authors:  Jamal Z Saleh; Linda H Lee; Stefan M Schieke; Paul R Hosking; Sam T Hwang
Journal:  JAAD Case Rep       Date:  2016-08-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.